Strides Pharma Science

Strides Pharma Science EBITDA per osake

EBITDA per osake yhtiöstä Strides Pharma Science (STAR.NS) 17.10.2026 päivämäärällä on 87,47 INR. Edellisenä vuonna EBITDA per osake oli 64,27 INR — muutos 36,10 % (korkeampi).

EBITDA per osake

87,47INR

YoY

36,10%

Viimeksi päivitetty:

EBITDA per osake yhtiöstä Strides Pharma Science on 2025 87,47 INR. EBITDA per osake yhtiöstä Strides Pharma Science oli 2024 64,27 INR. Se laskee 36,10% korkeampi edelliseen vuoteen verrattuna.

Strides Pharma Science EBITDA per osake historia

  • 3 vuotta

  • 10 vuotta

  • 25 vuotta

  • Maksimi

EBITDA per osake
Päivämäärä
EBITDA per osake
1.1.2018
45,91 INR
1.1.2019
29,46 INR
1.1.2020
60,83 INR
1.1.2021
70,50 INR
1.1.2022
−0,47 INR
1.1.2023
42,98 INR
1.1.2024
64,27 INR
1.1.2025
87,47 INR
Strides Pharma Science EBITDA per osake historia
VUOSIEBITDA per osakeYoY
87,47INR+36,10%
64,27INR+49,52%
42,98INR−9 310,61%
−0,47INR−100,66%
70,50INR+15,89%
60,83INR+106,53%
29,46INR−35,84%
45,91INR−22,53%
59,27INR+16,68%
50,80INR+22,35%
41,52INR−4,35%
43,41INR—

Hae nämä tiedot Eulerpool API:n kautta

100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia

Strides Pharma Science Osakeanalyysi

Mitä Strides Pharma Science tekee? Strides Pharma Science Ltd, trading under the ticker symbol STAR.NS and identified by ISIN INE939A01011, is a prominent entity within the Indian healthcare sector, specifically operating in the pharmaceuticals industry. Headquartered in Bangalore, Karnataka, the company has established itself as a significant player in the global market for generic and bio-pharmaceutical products. Strides Pharma Science Ltd went public on February 3, 2000, marking a pivotal moment in its corporate history and allowing it to expand its operational footprint. The organization currently employs approximately 2,850 full-time staff members who are dedicated to the development, manufacture, and distribution of its diverse product portfolio. The company’s business activities are primarily divided into two main segments: Pharmaceutical and Bio-pharmaceutical. This structural division allows the firm to focus on both traditional generic drugs and more complex biological therapeutics, ensuring a balanced approach to meeting varied market demands. Geographically, Strides Pharma Science Ltd has a broad international presence, serving markets across Africa, Australia, Asia excluding India, North America, Europe, India, and other regions. This extensive reach is supported by a robust manufacturing infrastructure comprising eight distinct units. These facilities are strategically located to optimize supply chain efficiency and regulatory compliance. In India, the company operates two manufacturing sites in Bengaluru, along with additional facilities in Puducherry and Chennai. Beyond its domestic operations, Strides maintains manufacturing capabilities in Singapore, Milan, Italy, Florida, United States, and Nairobi, Kenya. This global network enables the company to produce a wide array of dosage forms, including liquids, creams, ointments, soft gels, sachets, tablets, and modified-release formats. Notably, the company is also engaged in the specialized manufacturing of soft gelatin capsules. The firm’s product development strategy emphasizes intellectual property-led niche products, distinguishing it from competitors who may focus solely on standard generics. The therapeutic areas covered by Strides Pharma Science Ltd are extensive, with a strong emphasis on drugs for anti-retroviral, anti-malarial, anti-tuberculosis, and hepatitis treatments, as well as other infectious diseases. This focus on high-impact therapeutic segments underscores the company’s commitment to addressing critical global health challenges. By combining a strong manufacturing base with a diverse product range and a global distribution network, Strides Pharma Science Ltd continues to play a vital role in the pharmaceutical landscape, providing essential medicines to patients worldwide while maintaining its position as a key player in the Indian stock market. Strides Pharma Science on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Strides Pharma Science osakkeesta

Yhtiön Strides Pharma Science EBITDA per osake on 87,47 INR vuonna 2025.

EBITDA per osake yhtiöstä Strides Pharma Science muuttui arvosta 64,27 INR arvoon 87,47 INR, mikä edustaa 36,10 % muutosta. Arvo on korkeampi kuin edellisenä vuonna.

Eurpoolissa voit löytää EBITDA per osake Strides Pharma Science:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

EBITDA per osake jakaa EBITDAN liikkeeseen laskettujen osakkeiden lukumäärällä, näyttäen operatiivisen rahavoiton jaettuna osakemäärällä ennen poistoja ja rahoitusvaikutuksia.

Hae nämä tiedot Eulerpool API:n kautta

100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia

Tuloslaskelma — Strides Pharma Science

Kaikki tunnusluvut — Strides Pharma Science